Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|January 5, 2015
Key Points in the New Guidelines for High Cholesterol Management
Joseph Saseen, PharmD, from the Department of Clinical Pharmacy at the University of Colorado School of Pharmacy, discusses key points in the new guidelines for high cholesterol management.
Advertisement
Joseph Saseen, PharmD, from the Department of Clinical Pharmacy at the University of Colorado School of Pharmacy, discusses key points in the new guidelines for high cholesterol management.
This interview was recorded at the ASHP 2014 Midyear Clinical Meeting in Anaheim, California.
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
New Data Reshape Nonstatin Lipid Therapy Choices
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5